The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II trial of capecitabine (X) versus X plus erlotinib (E) in patients (pts) with metastatic colorectal cancer (mCRC): Differential impact of KRAS.
M. D. Vincent
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
S. Welch
Consultant or Advisory Role - Roche
Honoraria - Roche
D. Soulieres
Consultant or Advisory Role - Roche
Honoraria - Roche
M. S. Sanatani
Honoraria - Roche
F. Whiston
No relevant relationships to disclose
L. Stitt
No relevant relationships to disclose
A. O'Connell
No relevant relationships to disclose
M. J. MacKenzie
Consultant or Advisory Role - Roche
Honoraria - Roche
W. I. Kocha
Consultant or Advisory Role - Novartis
Honoraria - Novartis
I. G. Kerr
No relevant relationships to disclose
B. H. Dingle
No relevant relationships to disclose
A. Malpage
No relevant relationships to disclose